Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase 2 MDMA-assisted psychotherapy for PTSD with fMRI sub-study
2018-001718-13Phase 2Completed
- Sponsor
- MAPS Europe B.V.
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of midomafetamine in post-traumatic stress disorder (PTSD), sponsored by MAPS Europe B.V. Primary endpoint: Change in CAPS-5 Total Severity Score. Started Jan 2019; status: completed.
02
Drugs
midomafetamine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on 2018-001718-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001718-13.